FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792384496> ?p ?o ?g. }

• W2792384496 endingPage "461" @default.
• W2792384496 startingPage "461" @default.
• W2792384496 abstract "Background: Treatment-free remission (TFR)—that is, stopping tyrosine kinase inhibitor (TKI) therapy without loss of response—is an emerging treatment goal in chronic myeloid leukemia (CML). Objective: To evaluate TFR after discontinuation of second-line nilotinib therapy. Design: Single-group, phase 2, open-label study. (ClinicalTrials.gov: NCT01698905) Setting: 63 centers in 18 countries. Patients: Adults with CML in chronic phase who received TKI therapy for at least 3 years (>4 weeks with imatinib, then ≥2 years with nilotinib) and achieved MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1 IS]) while receiving nilotinib entered a 1-year consolidation phase. Those with sustained MR4.5 during consolidation were eligible to enter TFR. Interventions: Patients received nilotinib during consolidation; those who entered TFR stopped treatment. Patients with loss of major molecular response (MMR) (BCR-ABL1 IS ≤0.1%) or confirmed loss of MR4 (BCR-ABL1 IS ≤0.01%) during TFR reinitiated nilotinib treatment. Measurements: Proportion of patients without loss of MMR, confirmed loss of MR4, or treatment reinitiation within 48 weeks of stopping treatment (primary end point). Results: 163 patients who had switched from imatinib to nilotinib (for reasons including resistance, intolerance, and physician preference) enrolled in the study and entered the consolidation phase. Of these patients, 126 met the criteria for entering the TFR phase, and 73 (58% [95% CI, 49% to 67%]) and 67 (53% [CI, 44% to 62%]) maintained TFR at 48 weeks (primary end point) and 96 weeks, respectively. Of the 56 patients who reinitiated nilotinib therapy, 55 regained MMR or better and 52 regained MR4.5. None had CML progression to accelerated phase or blast crisis. Musculoskeletal pain was more frequent during the first 48 weeks after nilotinib discontinuation. Limitation: The study included a heterogeneous patient population and was not designed to compare outcomes between patients continuing and those stopping treatment. Conclusion: TFR seems achievable in patients with sustained MR4.5 after switching to nilotinib. Primary Funding Source: Novartis Pharmaceuticals Corporation." @default.
• W2792384496 created "2018-03-29" @default.
• W2792384496 creator A5000135837 @default.
• W2792384496 creator A5002600757 @default.
• W2792384496 creator A5003294629 @default.
• W2792384496 creator A5008022437 @default.
• W2792384496 creator A5013683304 @default.
• W2792384496 creator A5014346242 @default.
• W2792384496 creator A5018741449 @default.
• W2792384496 creator A5029712912 @default.
• W2792384496 creator A5030407146 @default.
• W2792384496 creator A5039390734 @default.
• W2792384496 creator A5041938151 @default.
• W2792384496 creator A5044589378 @default.
• W2792384496 creator A5045566016 @default.
• W2792384496 creator A5046495135 @default.
• W2792384496 creator A5046899067 @default.
• W2792384496 creator A5051359342 @default.
• W2792384496 creator A5053502496 @default.
• W2792384496 creator A5077014294 @default.
• W2792384496 creator A5077933082 @default.
• W2792384496 creator A5083591281 @default.
• W2792384496 date "2018-02-20" @default.
• W2792384496 modified "2023-10-16" @default.
• W2792384496 title "Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase" @default.
• W2792384496 cites W1510546584 @default.
• W2792384496 cites W1968747503 @default.
• W2792384496 cites W1973595070 @default.
• W2792384496 cites W1975541563 @default.
• W2792384496 cites W1990406235 @default.
• W2792384496 cites W1995670055 @default.
• W2792384496 cites W1998593414 @default.
• W2792384496 cites W2006917576 @default.
• W2792384496 cites W2019633460 @default.
• W2792384496 cites W2064367288 @default.
• W2792384496 cites W2068470589 @default.
• W2792384496 cites W2076372887 @default.
• W2792384496 cites W2076869962 @default.
• W2792384496 cites W2077812841 @default.
• W2792384496 cites W2117356576 @default.
• W2792384496 cites W2149898816 @default.
• W2792384496 cites W2154030078 @default.
• W2792384496 cites W2189113171 @default.
• W2792384496 cites W2260921597 @default.
• W2792384496 cites W2278657325 @default.
• W2792384496 cites W2313607879 @default.
• W2792384496 cites W2345930365 @default.
• W2792384496 cites W2473480037 @default.
• W2792384496 cites W2528188718 @default.
• W2792384496 cites W2592060299 @default.
• W2792384496 cites W1960354891 @default.
• W2792384496 doi "https://doi.org/10.7326/m17-1094" @default.
• W2792384496 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29459949" @default.
• W2792384496 hasPublicationYear "2018" @default.
• W2792384496 type Work @default.
• W2792384496 sameAs 2792384496 @default.
• W2792384496 citedByCount "100" @default.
• W2792384496 countsByYear W27923844962018 @default.
• W2792384496 countsByYear W27923844962019 @default.
• W2792384496 countsByYear W27923844962020 @default.
• W2792384496 countsByYear W27923844962021 @default.
• W2792384496 countsByYear W27923844962022 @default.
• W2792384496 countsByYear W27923844962023 @default.
• W2792384496 crossrefType "journal-article" @default.
• W2792384496 hasAuthorship W2792384496A5000135837 @default.
• W2792384496 hasAuthorship W2792384496A5002600757 @default.
• W2792384496 hasAuthorship W2792384496A5003294629 @default.
• W2792384496 hasAuthorship W2792384496A5008022437 @default.
• W2792384496 hasAuthorship W2792384496A5013683304 @default.
• W2792384496 hasAuthorship W2792384496A5014346242 @default.
• W2792384496 hasAuthorship W2792384496A5018741449 @default.
• W2792384496 hasAuthorship W2792384496A5029712912 @default.
• W2792384496 hasAuthorship W2792384496A5030407146 @default.
• W2792384496 hasAuthorship W2792384496A5039390734 @default.
• W2792384496 hasAuthorship W2792384496A5041938151 @default.
• W2792384496 hasAuthorship W2792384496A5044589378 @default.
• W2792384496 hasAuthorship W2792384496A5045566016 @default.
• W2792384496 hasAuthorship W2792384496A5046495135 @default.
• W2792384496 hasAuthorship W2792384496A5046899067 @default.
• W2792384496 hasAuthorship W2792384496A5051359342 @default.
• W2792384496 hasAuthorship W2792384496A5053502496 @default.
• W2792384496 hasAuthorship W2792384496A5077014294 @default.
• W2792384496 hasAuthorship W2792384496A5077933082 @default.
• W2792384496 hasAuthorship W2792384496A5083591281 @default.
• W2792384496 hasConcept C121608353 @default.
• W2792384496 hasConcept C126322002 @default.
• W2792384496 hasConcept C141071460 @default.
• W2792384496 hasConcept C197934379 @default.
• W2792384496 hasConcept C203092338 @default.
• W2792384496 hasConcept C2777413986 @default.
• W2792384496 hasConcept C2777583451 @default.
• W2792384496 hasConcept C2778375690 @default.
• W2792384496 hasConcept C2778715236 @default.
• W2792384496 hasConcept C2778729363 @default.
• W2792384496 hasConcept C2778820342 @default.
• W2792384496 hasConcept C535046627 @default.
• W2792384496 hasConcept C71924100 @default.
• W2792384496 hasConceptScore W2792384496C121608353 @default.

• next